Many tumors therefore express high levels of FASN, including breast, colorectal and endometrial cancers (Alo et al, 1996), and FASN inhibitors either kill tumor cells directly or sensitize them to other therapies such as 5-fluorouracil and trastuzumab (Herceptin) (Kridel et al, 2004; Menendez et al, 2006; Vazquez-Martin et al, 2007). Here, FASN is linked to neoplasm.